Psyence Biomedical Ltd

Discover how Psyence Biomedical’s debt‑free, $9.5 M‑cash position fuels its leap to Phase IIb psilocybin trials, positioning it as a rising force in psychedelic therapeutics.

Discover how Psyence Biomedical is pioneering psilocybin‑based longevity research, targeting aging biomarkers, and unlocking a multi‑billion‑dollar anti‑aging market.

Psyence Biomedical Ltd. has achieved a breakthrough in ibogaine production, a significant advancement in biotechnology that has led to a surge in the company’s stock price and positions it as a leader in the sector.